<SEC-DOCUMENT>0001214659-25-009732.txt : 20250627
<SEC-HEADER>0001214659-25-009732.hdr.sgml : 20250627
<ACCEPTANCE-DATETIME>20250627171621
ACCESSION NUMBER:		0001214659-25-009732
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250627
DATE AS OF CHANGE:		20250627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Biodexa Pharmaceuticals Plc
		CENTRAL INDEX KEY:			0001643918
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279994
		FILM NUMBER:		251087865

	BUSINESS ADDRESS:	
		STREET 1:		1 CASPIAN POINT
		STREET 2:		CASPIAN WAY
		CITY:			CARDIFF
		STATE:			X0
		ZIP:			CF10 4DQ
		BUSINESS PHONE:		44 (0)1235 888300

	MAIL ADDRESS:	
		STREET 1:		1 CASPIAN POINT
		STREET 2:		CASPIAN WAY
		CITY:			CARDIFF
		STATE:			X0
		ZIP:			CF10 4DQ

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Midatech Pharma Plc
		DATE OF NAME CHANGE:	20150602
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>o627252424b3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed pursuant to Rule 424(b)(3)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No.: 333-279994</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT No. 5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To the Prospectus dated May 9, 2025)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BIODEXA PHARMACEUTICALS PLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2,486,190,000 Ordinary Shares Representing 248,619
American Depositary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus supplement
No. 4 (the &ldquo;Prospectus Supplement&rdquo;) amends and supplements our prospectus contained in our Registration Statement on Form
F-1, as amended, effective as of May 9, 2025 (the &ldquo;Prospectus&rdquo;), related to the resale by the selling shareholders identified
in the Prospectus of up to an aggregate of 2,486,190,000 of our ordinary shares, nominal value &pound;0.000001 per share, represented
by 248,619 American Depositary Shares (the &ldquo;Depositary Shares&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Prospectus Supplement
is being filed in order to incorporate into and include in the Prospectus the information contained in our attached Form 6-K, filed with
the Securities and Exchange Commission on June 27, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Prospectus Supplement
should be read in conjunction with the Prospectus and is qualified by reference to the Prospectus except to the extent that the information
in this Prospectus Supplement supersedes the information contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Depositary Shares are
listed on the NASDAQ Capital Market under the symbol &ldquo;BDRX.&rdquo; The last reported closing price of Depositary Shares on the NASDAQ
Capital Market on June 26, 2025 was $0.9215.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our securities
involves risks. See &ldquo;Risk Factors&rdquo; beginning on page 9 of the Prospectus and in the documents incorporated by reference in
the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>______________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this Prospectus Supplement is June
27, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font-size: 8pt; text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of June 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number 001-37652</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Biodexa Pharmaceuticals PLC</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1 Caspian Point,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Caspian Way</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Cardiff, CF10 4DQ, United Kingdom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Form 20-F <FONT STYLE="font-family: Wingdings">x</FONT> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I></I></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Results of Annual General Meeting</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 27, 2025, Biodexa Pharmaceuticals PLC (the &ldquo;Company&rdquo;)
announced that at its Annual General Meeting (&ldquo;AGM&rdquo;) held on June 26, 2025, all of the resolutions set out in the Company&rsquo;s
notice of the AGM dated May 23, 2025 and furnished on a Report on Form 6-K with the Securities and Exchange Commission on May 23, 2025,
were duly passed. <U></U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>The information included
under the heading &ldquo;Results of Annual General Meeting&rdquo; shall be deemed to be incorporated by reference into the registration
statements on Form&nbsp;S-8 (File No. 333-209365) and Form&nbsp;F-3 (File No. 333-267932) of the Company (including any prospectuses forming
a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded
by documents or reports subsequently filed or furnished.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Press Release</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 27, 2025, the Company issued a press release announcing the
results of its AGM, a copy of which is attached hereto as Exhibit 99.<U>1.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>The information in
the attached Exhibit 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that Section, nor shall
it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange
Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="font-size: 8pt; text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SUBMITTED HEREWITH </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached to the Registrant&rsquo;s Form 6-K filing
for the month of June 2025 is:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; width: 9%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>Exhibit&nbsp;No.</B></P></TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 88%; border-bottom: black 1pt solid; font-size: 10pt"><B>Description</B></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; vertical-align: top; font-size: 10pt">99.1</TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1643918/000121465925009724/ex99_1.htm">Press Release dated June 27, 2025.</A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16pt">Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 16pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>Biodexa Pharmaceuticals PLC</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Date: June 27, 2025</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center">/s/ Stephen Stamp</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Stephen Stamp</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><I>Chief Executive Officer and Chief Financial Officer</I></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B><A NAME="a_001"></A>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="biodexa_logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center"><B>Biodexa Pharmaceuticals PLC</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: center">(&ldquo;<B>Biodexa</B>&rdquo; or the &ldquo;<B>Company</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 28.35pt; text-align: center"><B>Results of Annual General Meeting</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage
biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces
that at its Annual General Meeting held yesterday, all resolutions put to the Company&rsquo;s shareholders were duly passed.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 5.2pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 5.2pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman; font-size: 10pt">The
full text of, <I>inter alia</I>, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual
General Meeting on the Company's website at </FONT>https://biodexapharma.com/investors/corporate-governance//#agms.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0"><B>About Biodexa Pharmaceuticals PLC</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical
stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The
Company&rsquo;s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non Muscle Invasive
Bladder Cancer: tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive
rare/orphan brain cancer indications.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">eRapa is a proprietary oral tablet formulation of rapamycin,
also known as sirolimus. Rapamycin is an mTOR (<U>m</U>ammalian <U>T</U>arget <U>O</U>f <U>R</U>apamycin) inhibitor. mTOR has been shown
to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during
tumorgenesis.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Tolimidone is an orally delivered, potent and selective inhibitor
of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural
tissues, liver, and adipose tissue. Tolimidone demonstrates glycemic control via insulin sensitization in animal models of diabetes and
has the potential to become a first in class blood glucose modulating agent.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">MTX110 is a solubilised formulation of the histone deacetylase
(HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at
&nbsp;chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding&nbsp; systemic
toxicity.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Biodexa is supported by three proprietary drug delivery technologies
focused on improving the bio-delivery and bio-distribution of medicines. Biodexa&rsquo;s headquarters and R&amp;D facility is in Cardiff,
UK. For more information visit www.biodexapharma.com.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 100%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt"><IMG SRC="biodexa_logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Certain statements in this announcement may constitute &ldquo;forward-looking
statements&rdquo; within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management&rsquo;s belief or interpretation.
All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements.
In certain cases, forward-looking statements can be identified by the use of words such as &ldquo;plans&rdquo;, &ldquo;expects&rdquo;
or &ldquo;does not anticipate&rdquo;, or &ldquo;believes&rdquo;, or variations of such words and phrases or statements that certain actions,
events or results &ldquo;may&rdquo;, &ldquo;could&rdquo;, &ldquo;would&rdquo;, &ldquo;might&rdquo; or &ldquo;will be taken&rdquo;, &ldquo;occur&rdquo;
or &ldquo;be achieved.&rdquo; Forward-looking statements and information are subject to various known and unknown risks and uncertainties,
many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements
to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties
and other factors set out herein.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt 0; text-align: justify">Reference should be made to those documents that Biodexa shall
file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC,
which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections
or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above.
Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise
any forward-looking statements because of new information, future events or events otherwise arising.</P>

<P STYLE="font: 10pt Times New Roman; margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>biodexa_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 biodexa_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#4N,"XS /_; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( &D
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M)WMV-(XBA.M4H0JPE6I).I33]Z"ELVO/H>ST5S&P44 %% !10 44 %% !10
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MJ5,+A(QI4E3B_90NZE248*56K4FVSZ"K\#/VC?\ @O!\,O!_QM\1?LT_LE_
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M_P"S,YH5,JS.G5J2Q%:OA*D88OGG>G..(I0J0E:+4+.?*G%\K:9^FW_!QO\
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MEV2M^0'G@]#Q14C.:UO2O"5R?/\ $&GZ!<,J$"75X+"1A&&&0'O%)"!B"<'
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M=_S]1, =A^5+0 F!Z#\J6@!,#T'Y4M ";1Z#\J6C_A@$P/0?E2T &,=!^E%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
%!10!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
